Does the media favor MGNX or CNTB?

In the previous week, Connect Biopharma had 14 more articles in the media than MacroGenics. MarketBeat recorded 16 mentions for Connect Biopharma and 2 mentions for MacroGenics. MacroGenics' average media sentiment score of 0.00 beat Connect Biopharma's score of -0.01 indicating that MacroGenics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Connect Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CNTB or KROS?

In the previous week, Connect Biopharma had 12 more articles in the media than Keros Therapeutics. MarketBeat recorded 16 mentions for Connect Biopharma and 4 mentions for Keros Therapeutics. Keros Therapeutics' average media sentiment score of 0.00 beat Connect Biopharma's score of -0.01 indicating that Keros Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Connect Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Keros Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SION or CNTB more profitable?

Sionna Therapeutics' return on equity of -32.94% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Sionna Therapeutics N/A -32.94% -31.08% Connect Biopharma N/A -165.41% -121.58%

Does the media prefer SION or CNTB?

In the previous week, Connect Biopharma had 11 more articles in the media than Sionna Therapeutics. MarketBeat recorded 16 mentions for Connect Biopharma and 5 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.26 beat Connect Biopharma's score of -0.01 indicating that Sionna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Connect Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Connect Biopharma (CNTB) Competitors

$0.87 -0.01 (-1.21%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.90 +0.04 (+4.02%)

As of 10/9/2026 07:46 PM Eastern

Compare

CNTB vs. LYEL, MGNX, KROS, RNAC, and SION

Should you buy Connect Biopharma stock or one of its competitors? Connect Biopharma's main competitors and comparable companies include Lyell Immunopharma (LYEL), MacroGenics (MGNX), Keros Therapeutics (KROS), Cartesian Therapeutics (RNAC), and Sionna Therapeutics (SION). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Connect Biopharma compare to Lyell Immunopharma?

Connect Biopharma (NASDAQ:CNTB) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Connect Biopharma has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -920,285.25%. Lyell Immunopharma's return on equity of -91.62% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-165.41%	-121.58%
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%

Connect Biopharma has a beta of -0.16, indicating that its share price is 116% less volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market.

Connect Biopharma currently has a consensus price target of $6.14, indicating a potential upside of 606.08%. Lyell Immunopharma has a consensus price target of $40.86, indicating a potential upside of 369.08%. Given Connect Biopharma's higher possible upside, equities research analysts clearly believe Connect Biopharma is more favorable than Lyell Immunopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Connect Biopharma has higher revenue and earnings than Lyell Immunopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	913.07	-$55.48M	-$1.19	N/A
Lyell Immunopharma	$40K	5,334.88	-$274.45M	-$12.83	N/A

In the previous week, Connect Biopharma had 15 more articles in the media than Lyell Immunopharma. MarketBeat recorded 16 mentions for Connect Biopharma and 1 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 0.40 beat Connect Biopharma's score of -0.01 indicating that Lyell Immunopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Connect Biopharma	Neutral
Lyell Immunopharma	Neutral

Summary

Lyell Immunopharma beats Connect Biopharma on 9 of the 17 factors compared between the two stocks.

How does Connect Biopharma compare to MacroGenics?

MacroGenics (NASDAQ:MGNX) and Connect Biopharma (NASDAQ:CNTB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

Connect Biopharma has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$175.14M	1.36	-$74.62M	-$0.22	N/A
Connect Biopharma	$60K	913.07	-$55.48M	-$1.19	N/A

Connect Biopharma has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. MacroGenics' return on equity of -109.26% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-8.70%	-109.26%	-18.70%
Connect Biopharma	N/A	-165.41%	-121.58%

MacroGenics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.16, suggesting that its stock price is 116% less volatile than the broader market.

MacroGenics presently has a consensus price target of $6.33, suggesting a potential upside of 69.34%. Connect Biopharma has a consensus price target of $6.14, suggesting a potential upside of 606.08%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Connect Biopharma is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Connect Biopharma had 14 more articles in the media than MacroGenics. MarketBeat recorded 16 mentions for Connect Biopharma and 2 mentions for MacroGenics. MacroGenics' average media sentiment score of 0.00 beat Connect Biopharma's score of -0.01 indicating that MacroGenics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Connect Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Connect Biopharma beats MacroGenics on 9 of the 16 factors compared between the two stocks.

How does Connect Biopharma compare to Keros Therapeutics?

Connect Biopharma (NASDAQ:CNTB) and Keros Therapeutics (NASDAQ:KROS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by insiders. Comparatively, 12.6% of Keros Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Connect Biopharma had 12 more articles in the media than Keros Therapeutics. MarketBeat recorded 16 mentions for Connect Biopharma and 4 mentions for Keros Therapeutics. Keros Therapeutics' average media sentiment score of 0.00 beat Connect Biopharma's score of -0.01 indicating that Keros Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Keros Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Keros Therapeutics has higher revenue and earnings than Connect Biopharma. Keros Therapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	913.07	-$55.48M	-$1.19	N/A
Keros Therapeutics	$244.06M	0.97	$87.01M	-$3.70	N/A

Connect Biopharma presently has a consensus price target of $6.14, indicating a potential upside of 606.08%. Keros Therapeutics has a consensus price target of $20.50, indicating a potential upside of 71.55%. Given Connect Biopharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Connect Biopharma is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Connect Biopharma has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -21.40% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-165.41%	-121.58%
Keros Therapeutics	-256.60%	-21.40%	-19.79%

Connect Biopharma has a beta of -0.16, indicating that its share price is 116% less volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Summary

Connect Biopharma beats Keros Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Connect Biopharma compare to Cartesian Therapeutics?

Cartesian Therapeutics (NASDAQ:RNAC) and Connect Biopharma (NASDAQ:CNTB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

In the previous week, Connect Biopharma had 15 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 16 mentions for Connect Biopharma and 1 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.15 beat Connect Biopharma's score of -0.01 indicating that Cartesian Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cartesian Therapeutics	Neutral
Connect Biopharma	Neutral

87.0% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by company insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Connect Biopharma has lower revenue, but higher earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	76.17	-$130.30M	-$5.94	N/A
Connect Biopharma	$60K	913.07	-$55.48M	-$1.19	N/A

Cartesian Therapeutics has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.16, indicating that its stock price is 116% less volatile than the broader market.

Cartesian Therapeutics currently has a consensus target price of $32.60, indicating a potential upside of 362.41%. Connect Biopharma has a consensus target price of $6.14, indicating a potential upside of 606.08%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Connect Biopharma is more favorable than Cartesian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Connect Biopharma has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%
Connect Biopharma	N/A	-165.41%	-121.58%

Summary

Connect Biopharma beats Cartesian Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Connect Biopharma compare to Sionna Therapeutics?

Sionna Therapeutics (NASDAQ:SION) and Connect Biopharma (NASDAQ:CNTB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Sionna Therapeutics presently has a consensus target price of $42.33, suggesting a potential upside of 763.95%. Connect Biopharma has a consensus target price of $6.14, suggesting a potential upside of 606.08%. Given Sionna Therapeutics' higher probable upside, equities analysts clearly believe Sionna Therapeutics is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Connect Biopharma has higher revenue and earnings than Sionna Therapeutics. Sionna Therapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A
Connect Biopharma	$60K	913.07	-$55.48M	-$1.19	N/A

58.7% of Connect Biopharma shares are held by institutional investors. 5.1% of Sionna Therapeutics shares are held by company insiders. Comparatively, 22.6% of Connect Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Sionna Therapeutics' return on equity of -32.94% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-32.94%	-31.08%
Connect Biopharma	N/A	-165.41%	-121.58%

In the previous week, Connect Biopharma had 11 more articles in the media than Sionna Therapeutics. MarketBeat recorded 16 mentions for Connect Biopharma and 5 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.26 beat Connect Biopharma's score of -0.01 indicating that Sionna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Connect Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sionna Therapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.Comparatively, Connect Biopharma has a beta of -0.16, meaning that its share price is 116% less volatile than the broader market.

Summary

Connect Biopharma beats Sionna Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Connect Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTB vs. The Competition

Export

Metric	Connect Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$55.46M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-0.73	13.42	274.15	26.16
Price / Sales	913.07	1,234.32	589.97	94.50
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	1.16	17.17	11.21	6.34
Net Income	-$55.48M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-6.15%	-1.33%	-0.90%	-1.41%
1 Month Performance	-57.77%	-8.44%	-4.44%	-3.48%
1 Year Performance	-53.23%	14.02%	6.96%	1.16%

Connect Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTB Connect Biopharma	3.0915 of 5 stars	$0.87 -1.2%	$6.14 +606.1%	-56.1%	$55.46M	$60K	N/A	64	Analyst Forecast Analyst Revision
LYEL Lyell Immunopharma	2.757 of 5 stars	$9.44 +0.3%	$40.86 +333.0%	-53.8%	$231.16M	$40K	N/A	161
MGNX MacroGenics	1.4418 of 5 stars	$3.57 -1.0%	$6.33 +77.7%	+113.7%	$228.36M	$149.50M	N/A	293	News Coverage Positive News
KROS Keros Therapeutics	2.97 of 5 stars	$11.37 +1.0%	$20.50 +80.3%	-25.9%	$225.47M	$244.06M	N/A	92	News Coverage Analyst Upgrade
RNAC Cartesian Therapeutics	1.9501 of 5 stars	$7.44 +3.1%	$32.60 +338.1%	-30.2%	$224.91M	$2.80M	N/A	75

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTB) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Connect Biopharma (CNTB) Competitors

CNTB vs. LYEL, MGNX, KROS, RNAC, and SION

How does Connect Biopharma compare to Lyell Immunopharma?

Summary

How does Connect Biopharma compare to MacroGenics?

Summary

How does Connect Biopharma compare to Keros Therapeutics?

Summary

How does Connect Biopharma compare to Cartesian Therapeutics?

Summary

How does Connect Biopharma compare to Sionna Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB vs. The Competition

Connect Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Connect Biopharma (CNTB) Competitors

CNTB vs. LYEL, MGNX, KROS, RNAC, and SION

How does Connect Biopharma compare to Lyell Immunopharma?

Do insiders and institutionals believe in CNTB or LYEL?

Is CNTB or LYEL more profitable?

Which has more volatility and risk, CNTB or LYEL?

Do analysts rate CNTB or LYEL?

Which has higher earnings and valuation, CNTB or LYEL?

Does the media prefer CNTB or LYEL?

Summary

How does Connect Biopharma compare to MacroGenics?

Which has stronger earnings and valuation, MGNX or CNTB?

Is MGNX or CNTB more profitable?

Which has more volatility and risk, MGNX or CNTB?

Do analysts recommend MGNX or CNTB?

Does the media favor MGNX or CNTB?

Do institutionals & insiders hold more shares of MGNX or CNTB?

Summary

How does Connect Biopharma compare to Keros Therapeutics?

Do insiders and institutionals have more ownership in CNTB or KROS?

Does the media prefer CNTB or KROS?

Which has stronger valuation & earnings, CNTB or KROS?

Do analysts prefer CNTB or KROS?

Is CNTB or KROS more profitable?

Which has more risk & volatility, CNTB or KROS?

Summary

How does Connect Biopharma compare to Cartesian Therapeutics?

Does the media favor RNAC or CNTB?

Do insiders and institutionals believe in RNAC or CNTB?

Which has preferable earnings & valuation, RNAC or CNTB?

Which has more volatility & risk, RNAC or CNTB?

Do analysts recommend RNAC or CNTB?

Is RNAC or CNTB more profitable?

Summary

How does Connect Biopharma compare to Sionna Therapeutics?

Do analysts prefer SION or CNTB?

Which has higher earnings & valuation, SION or CNTB?

Do institutionals and insiders hold more shares of SION or CNTB?

Is SION or CNTB more profitable?

Does the media prefer SION or CNTB?

Which has more volatility and risk, SION or CNTB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB vs. The Competition

Connect Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools